[塞来昔布与吲哚美辛对大鼠急性胃损伤的影响]

[Celecoxib vs indomethacin and acute gastric lesions in rats].

作者信息

Laudanno O M, Esnarriaga J M, Cesolari J A, Maglione C B, Aramberry L J, Sambrano J S, Piombo G, Rista L

机构信息

Cátedra de Patología Médica III e Histología y Embriología, Facultad de Ciencias Médicas, Universidad Nacional de Rosario, Argentina.

出版信息

Medicina (B Aires). 2000;60(2):221-4.

PMID:10962812

Abstract

In 5 random groups of Wistar rats (n = 15 for each group), ulcerogenic doses of NSAIDs COX-1-COX-2 inhibitors such as indomethacin were compared with Celecoxib (COX-2 inhibitor); the production of antrum gastric ulcers and bowel and colon necrotic areas was studied. Celecoxib was given each 12 hs orally and subcutaneously during 5 days and gastrointestinal lesions were not found; in contrast, Celecoxib given after indomethacin aggravated antrum gastric ulcers (p < 0.001); intestinal massive necrosis and death were observed in all the rats. We conclude that Celecoxib does not induce gastrointestinal lesions in healthy mucosa; in contrast, Celecoxib amplifies the gastrointestinal lesions induced by indomethacin.

摘要

在5组随机分组的Wistar大鼠中（每组n = 15），将致溃疡剂量的非甾体抗炎药COX - 1 - COX - 2抑制剂（如吲哚美辛）与塞来昔布（COX - 2抑制剂）进行比较；研究胃窦胃溃疡以及肠道和结肠坏死区域的产生情况。塞来昔布在5天内每12小时口服和皮下给药一次，未发现胃肠道病变；相比之下，在吲哚美辛给药后给予塞来昔布会加重胃窦胃溃疡（p < 0.001）；在所有大鼠中均观察到肠道大面积坏死和死亡。我们得出结论，塞来昔布不会在健康黏膜中诱发胃肠道病变；相反，塞来昔布会放大由吲哚美辛诱发的胃肠道病变。